Vpac2 Receptor Neurons is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Neurons expressing the vasoactive intestinal peptide receptor 2 (VPAC2), also known as VIP receptor 2 or Vasoactive Intestinal Peptide Receptor 2, are widely distributed throughout the central nervous system. VPAC2 is a G protein-coupled receptor that binds both vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP). These neurons play important roles in neuroprotection, circadian rhythm regulation, and immune modulation.
VPAC2-expressing neurons are found in:
- Suprachiasmatic nucleus (SCN) — key location for circadian rhythm regulation
- Cerebral cortex — throughout cortical layers
- Hippocampus — in all hippocampal regions
- ** — particularly in central nucleus
- HAmygdalaypothalamus** — in multiple hypothalamic nuclei
- Brainstem — in regions controlling autonomic functions
VPAC2 neurons in the SCN:
- Mediate VIP signaling in circadian clock
- Synchronize circadian rhythms
- Regulate light-entrained responses
- Control sleep-wake cycles
VPAC2 activation provides neuroprotective effects through:
- Anti-apoptotic signaling (via PACAP)
- Anti-inflammatory responses
- Reduction of excitotoxicity
- Promotion of neural progenitor proliferation
¶ Learning and Memory
- Modulates hippocampal synaptic plasticity
- Influences memory consolidation
- Involved in fear conditioning
- VPAC2 on neurons interacts with immune cells
- Modulates neuroinflammation
- Affects blood-brain barrier function
- VPAC2/PACAP signaling is neuroprotective in AD
- PACAP deficiency observed in AD brains
- VPAC2 agonists being explored as therapy
- May reduce amyloid toxicity
- VPAC2 provides dopaminergic neuroprotection
- PACAP-VPAC2 axis supports neuron survival
- Potential for disease modification
- VPAC2 modulates neuroinflammation
- PACAP therapy shows promise in MS models
¶ Stroke and Ischemia
- VPAC2 activation reduces ischemic damage
- Promotes neuronal survival after stroke
VPAC2 couples to Gs proteins:
- Activates adenylyl cyclase → increases cAMP
- Stimulates PKA signaling
- Activates MAP kinase pathways
- Modulates calcium channels
VPAC2 is a therapeutic target for:
- Circadian rhythm disorders
- Neurodegenerative diseases
- Stroke treatment
- Inflammatory conditions
The study of Vpac2 Receptor Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.